AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15715683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg o.d. for 3 months
Number of subjects: 37
Study 15715683 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 37
Study 13679489 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole puncture technique using a thumbtack-shaped polycarbonate peg for 14 days during HD sessions.
Number of subjects: 37
Study 10473911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar infarct (posterior inferior cerebellar artery territory in 9 patients, superior cerebellar artery in 6, anterior inferior cerebellar artery in 2, nonterritorial in 1)
Number of subjects: 105
Study 10473911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar infarct
Number of subjects: 105
Study 9371403 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP (bleomycin, etoposide, and cisplatin) chemotherapy
Number of subjects: 788
Study 9371403 — intervention group
Group type: COMPARATOR
Intervention: Control donors
Number of subjects: 788
Study 1345033 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure drainage (PPD)
Number of subjects: 28
Study 1345033 — intervention group
Group type: COMPARATOR
Intervention: Traditional negative pressure drainage (NPD)
Number of subjects: 28
Study 4019953 — intervention group
Group type: COMPARATOR
Intervention: 6‐methyl‐prednisolone (1 mg/kg) intravenous bolus
Number of subjects: 12
Study 4019953 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐methyl‐prednisolone (32 mg once a day, orally) for 8 days
Number of subjects: 12
Study 4019953 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 31228507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 76
Study 29522226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% ophthalmic suspension once daily
Number of subjects: 35
Study 29522226 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.1% ophthalmic suspension three times a day
Number of subjects: 35
Study 26386921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 4 mg/kg twice-daily (can be down-titrated to 2 mg/kg if not tolerated)
Number of subjects: 33
Study 26386921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 4 mg/kg twice-daily
Number of subjects: 33
Study 24406660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body integration practices and cooperative activities
Number of subjects: 0
Study 22994348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite allergen extracts
Number of subjects: 509
Study 22994348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 22994348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 509
Study 19574861 — intervention group
Group type: EXPERIMENTAL
Intervention: <0.5 mA stimulation threshold
Number of subjects: 69
Study 19574861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐0.64 mA stimulation threshold
Number of subjects: 69
Study 19574861 — intervention group
Group type: EXPERIMENTAL
Intervention: >0.65 mA stimulation threshold
Number of subjects: 69
Study 17321581 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen mix (sublingual immunotherapy) for 2 years
Number of subjects: 204
Study 17321581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 17321581 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen mix (sublingual immunotherapy)
Number of subjects: 204
Study 15224087 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in hand function
Number of subjects: 565
Study 15224087 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in bladder and bowel function
Number of subjects: 565
Study 15224087 — intervention group
Group type: EXPERIMENTAL
Intervention: Other SCI-related impairments
Number of subjects: 565
Study 11435009 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40
Study 11435009 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 40
Study 8333263 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with brief revision training
Number of subjects: 16
Study 8333263 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry without revision training
Number of subjects: 16
Study 3013568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam 1g plus ampicillin 2g every 8 hours
Number of subjects: 75
Study 3013568 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2g every 8 hours
Number of subjects: 75
Study 28924870 — intervention group
Group type: EXPERIMENTAL
Intervention: MR309
Number of subjects: 124
Study 26947668 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon extract (6 g daily for 6 weeks)
Number of subjects: 40
Study 26947668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25563795 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured hypocaloric diet
Number of subjects: 118
Study 25563795 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 118
Study 25563795 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of high-fat dairy (all women)
Number of subjects: 118
Study 23430142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% (w/w) AHYP cream applied twice daily for 4 weeks
Number of subjects: 15
Study 23430142 — intervention group
Group type: COMPARATOR
Intervention: Control cream applied twice daily for 4 weeks
Number of subjects: 15
Study 21138533 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (2 g/day) and antioxidant vitamins C (1 g/day) and E (400 IU/day)
Number of subjects: 95
Study 18426991 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 131
Study 18426991 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 131
Study 16160711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0
Study 16160711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12525463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 micro g every 3 h for a maximum of three doses)
Number of subjects: 80
Study 12525463 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 micro g every 3 h for a maximum of three doses)
Number of subjects: 80
Study 10865219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (25 mg twice daily) plus calcium (1000 mg/day)
Number of subjects: 118
Study 10865219 — intervention group
Group type: COMPARATOR
Intervention: Intermittent etidronate (400 mg/day for 14 days) followed by calcium (1000 mg/day for 76 days)
Number of subjects: 118
Study 9095567 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent position
Number of subjects: 100
Study 9095567 — intervention group
Group type: COMPARATOR
Intervention: Erect position
Number of subjects: 100
Study 1363082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% befunolol
Number of subjects: 30
Study 1363082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3321872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 204
Study 3321872 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 204
Study 30373342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided popliteal sciatic nerve combined saphenous nerve block
Number of subjects: 60
Study 30373342 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 60
Study 26986055 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% body weight in seated position
Number of subjects: 15
Study 26986055 — intervention group
Group type: EXPERIMENTAL
Intervention: 90/90 position
Number of subjects: 15
Study 25617159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (min 0.2 µg/kg/h‐max 1.0 µg/kg/h)
Number of subjects: 64
Study 25617159 — intervention group
Group type: COMPARATOR
Intervention: Propofol (min 1.0 mg/kg/h‐max 3.0 mg/kg/h)
Number of subjects: 64
Study 25617159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 64
Study 25617159 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 64
Study 23724525 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for three months
Number of subjects: 104
Study 23724525 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (MPA) for three months
Number of subjects: 104
Study 23724525 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for six months
Number of subjects: 104
Study 23724525 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (MPA) for six months
Number of subjects: 104
Study 20816027 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d)
Number of subjects: 36
Study 20816027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20816027 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 36
Study 19832967 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 19832967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 17084114 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day immobilization with a soft cervical collar
Number of subjects: 70
Study 17084114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day immobilization with a soft cervical collar
Number of subjects: 70
Study 15641760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (5 ppm; total amount 1.25 mg F)
Number of subjects: 15
Study 15641760 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated control milk
Number of subjects: 15
Study 11393606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent smoking treatment (MST)
Number of subjects: 150
Study 11393606 — intervention group
Group type: EXPERIMENTAL
Intervention: MST plus generalization training of smoking cessation to drug and alcohol cessation (MST+G)
Number of subjects: 150
Study 11393606 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 150
Study 11393606 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 150
Study 11393606 — intervention group
Group type: EXPERIMENTAL
Intervention: MST+G
Number of subjects: 150
Study 11393606 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 150
Study 9252088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (500 mg/day) plus methotrexate (10 mg/week)
Number of subjects: 25
Study 9252088 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid plus placebo
Number of subjects: 25
Study 8303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 57
Study 8303108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 3795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (18 mg yohimbine/day)
Number of subjects: 19
Study 3795978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31694861 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1502 5 mg
Number of subjects: 166
Study 31694861 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1502 10 mg
Number of subjects: 166
Study 31694861 — intervention group
Group type: EXPERIMENTAL
Intervention: RVT-1502 15 mg
Number of subjects: 166
Study 31694861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 29394207 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections of local anesthetic with corticosteroid (n = 200)
Number of subjects: 400
Study 29394207 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only (lidocaine) (n = 200)
Number of subjects: 400
Study 29394207 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 400
Study 29394207 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 400
Study 29394207 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone or dexamethasone
Number of subjects: 400
Study 27107532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight-supported treadmill training (BWSTT)
Number of subjects: 45
Study 27107532 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without bodyweight support
Number of subjects: 45
Study 27107532 — intervention group
Group type: COMPARATOR
Intervention: Overground gait training
Number of subjects: 45
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisometropia measurement
Number of subjects: 358
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of change in anisometropia
Number of subjects: 358
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniso-axial length (AL) measurement
Number of subjects: 358
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between changes in anisometropia and aniso-AL
Number of subjects: 358
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between changes in anisometropia and myopia progression
Number of subjects: 358
Study 24576881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anisometropia and myopia progression correlation
Number of subjects: 358
Study 23872228 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring health-related feedback
Number of subjects: 0
Study 23872228 — intervention group
Group type: COMPARATOR
Intervention: Threatening health-related feedback
Number of subjects: 0
Study 20713915 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids
Number of subjects: 28100
Study 20713915 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids
Number of subjects: 28100
Study 20713915 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids
Number of subjects: 28100
Study 20713915 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (including ω3 and ω6)
Number of subjects: 28100
Study 18332704 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 18332704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation
Number of subjects: 0
Study 18332704 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration without endotracheal intubation
Number of subjects: 0
Study 16308014 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards PERIMOUNT Magna
Number of subjects: 63
Study 16308014 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards PERIMOUNT
Number of subjects: 63
Study 16308014 — intervention group
Group type: COMPARATOR
Intervention: Edwards Prima Plus
Number of subjects: 63
Study 12610843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 48
Study 12610843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 48
Study 12610843 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 48
Study 10318654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (CA group)
Number of subjects: 1689
Study 10318654 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine and aspirin (TA group)
Number of subjects: 1689
Study 8905888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 29
Study 8905888 — intervention group
Group type: COMPARATOR
Intervention: Standard chest physical therapy and postural drainage (CPT/PD)
Number of subjects: 29
Study 1899393 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG-induced ovulation with IUI
Number of subjects: 48
Study 1899393 — intervention group
Group type: COMPARATOR
Intervention: hCG-induced ovulation with natural intercourse
Number of subjects: 48
Study 1899393 — intervention group
Group type: EXPERIMENTAL
Intervention: spontaneous LH surge with IUI
Number of subjects: 48
Study 1899393 — intervention group
Group type: COMPARATOR
Intervention: spontaneous ovulation with timed intercourse
Number of subjects: 48
Study 6133166 — intervention group
Group type: EXPERIMENTAL
Intervention: Received formula sample packet
Number of subjects: 448
Study 6133166 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive formula sample packet)
Number of subjects: 448
Study 31328311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-guided CB-PVI
Number of subjects: 60
Study 31328311 — intervention group
Group type: COMPARATOR
Intervention: Conventional CB-PVI
Number of subjects: 60
Study 28270280 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPA on high-pitch scanning mode at 70 kV tube voltage with 15 ml contrast medium (Group B)
Number of subjects: 70
Study 28270280 — intervention group
Group type: COMPARATOR
Intervention: CTPA on conventional scanning mode (120 kV, 80 ml contrast medium) (Group A)
Number of subjects: 70
Study 26899038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfurous water (SW) group (N=47)
Number of subjects: 140
Study 26899038 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sulfurous water (NSW) group (N=50)
Number of subjects: 140
Study 26899038 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=43)
Number of subjects: 140
Study 24805262 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (30 mg/kg/d)
Number of subjects: 60
Study 24805262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22492529 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 0
Study 22492529 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 0
Study 19463518 — intervention group
Group type: COMPARATOR
Intervention: Vigorous exercise frequency (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921
Study 19463518 — intervention group
Group type: COMPARATOR
Intervention: Vigorous exercise frequency in men <50 years of age (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921
Study 19463518 — intervention group
Group type: COMPARATOR
Intervention: Vigorous exercise frequency in joggers (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week)
Number of subjects: 16921
Study 17075807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week)
Number of subjects: 154
Study 17075807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 17075807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 154
Study 14717742 — intervention group
Group type: EXPERIMENTAL
Intervention: DX (derivative crossing)
Number of subjects: 19
Study 14717742 — intervention group
Group type: EXPERIMENTAL
Intervention: PX (point of crossing)
Number of subjects: 19
Study 14717742 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ (point of VCO(2) equivalent rise)
Number of subjects: 19
Study 12508631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 57
Study 12508631 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 9447367 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary care
Number of subjects: 150
Study 9447367 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 150
Study 7931253 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A 1 mg
Number of subjects: 24
Study 7931253 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A 12 mg
Number of subjects: 24
Study 7931253 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A 24 mg
Number of subjects: 24
Study 7931253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3277680 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 326
Study 3277680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 326
Study 3277680 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 326
Study 31357229 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG)
Number of subjects: 33
Study 31357229 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 28438450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular MONOCRYL and DERMABOND (SMD)
Number of subjects: 129
Study 28438450 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 129
Study 28438450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular MONOCRYL and DERMABOND (SMD) and Staples
Number of subjects: 129
Study 26173928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 6091)
Number of subjects: 9415
Study 26173928 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 3324)
Number of subjects: 9415
Study 23274077 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator Group (SG)
Number of subjects: 27
Study 23274077 — intervention group
Group type: COMPARATOR
Intervention: Conventional Group (CG)
Number of subjects: 27
Study 23274077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 27
Study 21571733 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology (AT) including assistive devices and splints
Number of subjects: 70
Study 21571733 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology (AT)
Number of subjects: 70
Study 21571733 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 70
Study 18364321 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiwanese traditional herbal diet (TTHD) consisting of analgesic herbs (paeony root: licorice root=1:1) and Taiwanese tonic vegetable soup (Lilii bulbus, Nelumbo seed, and Jujube fruit)
Number of subjects: 2466
Study 18364321 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital diet (reference group)
Number of subjects: 2466
Study 18364321 — intervention group
Group type: COMPARATOR
Intervention: Taiwanese tonic vegetable soup without analgesic herbs (control group)
Number of subjects: 2466